Study of serum adiponectin levels in type2 diabetes mellitus patients on treatment
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2022/01/039750
- Lead Sponsor
- kasturba medical college
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients diagnosed as T2DM according to ADA guidelines Age 40-70 years
on Oral Anti-diabetic Drugs for at least of 6 months duration.
Group 1 : Control â??Type 2 diabetics Not on any medication
Sample Size : 10
Group 2 : Type 2 diabetics already on Glimepiride + Metformin
sample size: 30
Group 3 : Type2 diabetics already on DPP4 inhibitor(vildagliptin) + Metformin
Sample Size : 30
Type 1 DM patients
Patients on insulin therapies for type2 DM
Patients with DKA/acute illness
Patients on drugs known to alter adiponectin levels i.e. rosiglitazone, Temocapril, Candesartan, pravastatin, Efonidipine, nebivolol, niacin.
Impaired renal (CKD) & liver function (CLD)
Patients with serious cardiovascular disease & cerebrovascular
conditions within 6 months before study enrolment
Conditions that can alter HBA1C estimation â??known
hematological, genetic variants
Women who are pregnant or breastfeeding and diagnosed with
Gestational diabetes
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method